ALK inhibitors and ROS1 inhibitors
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ALK inhibitors and ROS1 inhibitors, covering 2025-12-30 to 2025-12-30. Get the full timeline:
Most recent: Clinical Trial Update: Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway